Sheel Biotech Limited IPO Details
SME
Sheel Biotech IPO opens for subscription on 30 Sep 2025 and closes on 03 Oct 2025. The IPO will be listed on NSE with the tentative listing date set for 08 Oct 2025.
Sheel Biotech IPO price band has been fixed at ₹59 – ₹63 per share.The face value is ₹10 per share with a lot size of 2000.
Sheel Biotech IPO total issue size comprises 54,00,000 shares (aggregating up to ₹34.02 Cr.). This includes a fresh issue of 54,00,000 shares (aggregating up to ₹34.02 Cr.). Pre-issue shareholding stands at 1,49,52,550, which will increase to 2,03,52,550 post-issue.
Sheel Biotech IPO Lot Size : Individual Minimum is 2 lots (4,000 shares) amounting to ₹252,000. Individual Maximum is 2 lots (4,000 shares) amounting to ₹252,000. SHNI Minimum is 3 lots (6,000 shares) amounting to ₹378,000. SHNI Maximum is 7 lots (14,000 shares) amounting to ₹882,000. BHNI Minimum is 8 lots (16,000 shares) amounting to ₹1,008,000.
The Lead Managers for Sheel Biotech IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Narnolia Financial Services Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Mansi Share & Stock Broking Private Limited. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Sheel Biotech Limited RHP.
Sheel Biotech IPO Details
Sheel Biotech IPO Subscription
Sheel Biotech IPO Application Wise Breakup
Sheel Biotech IPO Dates
- 30 Sep 2025Opening dateOPD
- 03 Oct 2025Closing dateCOD
- 06 Oct 2025Allotment Date BOA
- 07 Oct 2025Initiation of RefundsIOR
- 07 Oct 2025Credit of SharesCOS
- 08 Oct 2025Listing dateLID
Sheel Biotech IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 4000 | ₹252,000 |
| Individual Maximum | 2 | 4000 | ₹252,000 |
| SHNI Minimum | 3 | 6000 | ₹378,000 |
| SHNI Maximum | 7 | 14000 | ₹882,000 |
| BHNI Minimum | 8 | 16000 | ₹1,008,000 |
Sheel Biotech IPO Reservation
Promoter Holding
Sheel Biotech IPO Valuations
Sheel Biotech Financial Information
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 105.98 | 105.95 | 93.89 | 93.08 |
| Total Income | 3.99 | 92.55 | 80.19 | 71.07 |
| Profit After Tax | 0.48 | 10.51 | 5.08 | 4.51 |
| Net Worth | 73.21 | 72.73 | 63.54 | 59.75 |
| Reserves and Surplus | 69.07 | 68.58 | 59.4 | 55.61 |
| Total Borrowing | 25.22 | 23.54 | 19.17 | 23.58 |
| Amount in ₹ Crore | ||||
About Sheel Biotech IPO
Incorporated in November 1991, Sheel Biotech Limited specializes in biotechnology, floriculture, greenhouses, and organic projects.
The company grows and supplies various plants for field crops, fruits, vegetables, and ornamentals through tissue culture and organic farming.
The company manufactures and maintains greenhouses, provides farmer services, and offers training through FPOs.
They also deliver landscaping services to the government and private sectors.
The company holds ISO 9001:2015, 14001:2015, and 45001:2018 certifications, reflecting its commitment to quality, environmental responsibility, and safety.
The company's Research and Development laboratory is recognized by the Department of Biotechnology (DBT) and the Department of Science and Technology (DST) of the Government of India.
Sheel Biotech offers a diverse range of services and products, including:
- Planting Material: Utilizing tissue culture and hydroponics, the company produces high-quality, disease-free planting materials for various crops such as fruits, floriculture, forestry, and ornamentals.
- Horticultural Projects: Sheel Biotech designs and implements greenhouses, centers of excellence, integrated packhouses, and other turnkey projects, incorporating modern technologies like climate control, automation, drip irrigation, and fertigation to optimize crop yield and quality.
- Organic Adoption and Certification: The company assists farmers in transitioning to organic farming by providing adoption and certification services in line with the National Programme for Organic Production (NPOP) and the Participatory Guarantee System (PGS).
- Farmer Producer Organization (FPO) Management: Sheel Biotech supports the establishment and management of FPOs, offering training, skill development, and market linkage assistance to enhance farmers' access to better services and inputs.
- Skill Development: The company conducts training programs, seminars, workshops, and exposure trips to educate farmers and agripreneurs on modern agricultural practices and techniques.
As of September 30, 2024, the Company has 160 permanent employees on its payroll.
Strength Of Sheel Biotech IPO
1. Our ability to capitalize the opportunities and growth in the Tissue Culture industry.
2. Promotion of Tissue Culture industry by the Government of India.
3. Cordial relations with our clients.
Risk Of Sheel Biotech IPO
1. We depend on government tenders for our revenue of operations. Any unavailability or any failure to secure these tenders in the future may adversely affect our business operations and financial conditions.
2. One of our business segment Tissue culture demands the highest level of precautions in quality, storage, and temperature management. Any negligence in these areas can significantly affect our business outcomes.
3. We use the proper techniques in the whole tissue culture process. Any Ineffective sterilization of tools and media can lead to contamination, which would adversely affect the entire culture.
4. Our business is subject to seasonal fluctuations that could result in delays or disruptions to our operations during the critical periods of our projects and cause severe damage to our premises and equipments.
5. Our Company is involved in certain legal proceedings/litigations. Any adverse decision in such proceedings may render us/them liable to penalties and may adversely affect our business and result of operations.
6. Our success depends largely upon the services of our Directors, Promoters and other Key Managerial Personnel and our ability to attract and retain them. Demand for Key Managerial Personnel in the industry is intense and our inability to attract and retain Key Managerial Personnel may affect the operations of our Company.
7. Any disruption, breakdown or shutdown of our research and development may have a material adverse effect on our tissue culture segment, financial condition, results of operations and cash flows.
8. We have had negative cash flows in the past and may continue to have negative cash flows in the future.
9. Our Company does not own the premises through which we conduct our business operations.
10. There have been instances of delay in filing of GST and ESIC returns of the Company. We may be subject to regulatory actions and penalties for any such delays and our business, financial condition and reputation may be adversely affected.
Objectives Sheel Biotech IPO
1. Capital Expenditure Requirement
2. Working Capital Requirement
3. General Corporate Purposes
Company Contact Details
Sheel Biotech Ltd.
8 Balaji Estates
, 2nd Floor, Block-C, Guru Ravidas Marg
Kalkaji
South Delhi, New Delhi, 110019
Phone: +91 88511 - 8980
Email: compliance@sheelbiotech.com
Website: http://www.sheelbiotech.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Market Maker
Market Maker Reports